H.C. Wainwright raised the firm’s price target on Perspective Therapeutics (CATX) to $12 from $10 and keeps a Buy rating on the shares. The firm says Sanofi’s deprioritization of Alphamedix eliminates a competitor for Perspective .
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline
- Undervalued Radiopharma Pipeline and Manufacturing Platform Underpin Buy Rating and $18 Target
- Perspective Therapeutics outlines 2026 clinical and manufacturing priorities
- Perspective Therapeutics provides business updates, strategic priorities
- Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data